Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

1.58USD
21 Sep 2018
Change (% chg)

$-0.02 (-1.25%)
Prev Close
$1.60
Open
$1.59
Day's High
$1.59
Day's Low
$1.52
Volume
143,523
Avg. Vol
35,625
52-wk High
$5.53
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Reports Q2 Loss Per Share $0.45
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, AVENUE'S CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $8.9 MILLION.  Full Article

Mustang Bio Q2 Loss Per Share $0.19
Tuesday, 14 Aug 2018 

Mustang Bio Inc ::MUSTANG BIO REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.19.ON TRACK TO FILE AN IND IN Q4 FOR CD123 CAR T, MB-102.  Full Article

Mustang Bio Expects To Apply For Permission For Human Trials Of MB-102 Drug In Q4
Thursday, 19 Jul 2018 

July 19 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO COMPLETES PRE-IND MEETING WITH FDA FOR MB-102 (CD123 CAR T).MUSTANG BIO INC - WILL CONTINUE ITS EFFORTS ON ITS IND FILING TO FDA FOR MB-102..MUSTANG BIO INC - EXPECT TO SUBMIT AN IND FILING FOR MB-102 IN Q4 AS PLANNED.MUSTANG BIO - ANTICIPATE MANUFACTURING FACILITY WILL BE READY TO PROCESS PATIENT CELLS IN NEXT FEW MONTHS.  Full Article

Fortress Biotech Files For Mixed Shelf Of Up To $50 Mln - SEC Filing
Saturday, 7 Jul 2018 

July 6 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH INC FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING.  Full Article

Fortress Biotech Says US FDA Grants Fast Track Designation to Cyprium's CUTX-101
Monday, 2 Jul 2018 

July 2 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH ANNOUNCES CYPRIUM THERAPEUTICS’ CUTX-101 (COPPER HISTIDINATE) GRANTED FDA FAST TRACK DESIGNATION FOR TREATMENT OF CLASSIC MENKES DISEASE.  Full Article

Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain
Monday, 21 May 2018 

May 21 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL.AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS.AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019.  Full Article

Mustang Bio Reports Q4 Financial Results
Friday, 30 Mar 2018 

March 29 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.FORTRESS BIOTECH - ‍AS OF DEC 31, 2017, MUSTANG'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH TOTALED $61.5 MILLION.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

BRIEF-Mustang Bio Reports Q4 Financial Results

* MUSTANG BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS